- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00138840
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for the Induction of Clinical Response in Patients With Crohn's Disease
STA-5326 is an experimental drug that has been shown to block the release of interleukin-12 from peripheral blood mononuclear cells. Given this activity on the immune system, STA-5326 mesylate is a potential treatment for various autoimmune diseases, such as Crohn's disease, that are mediated by the inappropriate expression of Th1 cytokines.
This study is evaluating the use of STA-5326 mesylate in patients with moderate to severe, active Crohn's disease. Study visits include a screening visit, 9 treatment period visits over 6 months and a follow-up visit that will occur 30 days following the end of treatment. Study drug treatment will continue for up to 6 months.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N4N1
- University of Calgary Health Sciences
-
-
Ontario
-
London, Ontario, Canadá, N6A 4G5
- London Health Science Center South Street Campus
-
London, Ontario, Canadá, N6A 5A5
- London Health Science Center University Campus
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá, S7K1N4
- Saskatoon Medical Specialists
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Gastroenterology Associates
-
-
California
-
Anaheim, California, Estados Unidos, 92801
- Advanced Clinical Research Institute
-
Orange, California, Estados Unidos, 92868
- Community Clinical Trials
-
San Diego, California, Estados Unidos, 92123
- Medical Associates Research Group
-
-
Florida
-
Hollywood, Florida, Estados Unidos, 33021
- Southern Clinical Research Consultants
-
Jacksonville, Florida, Estados Unidos, 32204
- Borland Groover Clinic
-
Miami, Florida, Estados Unidos, 33173
- Miami Research Associates
-
Palm Harbor, Florida, Estados Unidos, 34684
- Advanced Gastroenterology Highland Lakes Medical Center
-
Winter Park, Florida, Estados Unidos, 32789
- Shafran Gastroenterology Center
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- Atlanta Gastroenterology
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Univ. of Louisville Clinical Research Unit
-
-
Maryland
-
Chevy Chase, Maryland, Estados Unidos, 20815
- Chevy Chase Clinical Research
-
Laurel, Maryland, Estados Unidos, 20707
- Maryland Digestive Disease Research
-
Silver Spring, Maryland, Estados Unidos, 20901
- Capital Gastroenterology Consultants, P.A.
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02118
- Boston Medical Center
-
-
Missouri
-
St. Louis, Missouri, Estados Unidos, 63128
- St. Louis Center for Clinical Research
-
-
New Jersey
-
Cedar Knolls, New Jersey, Estados Unidos, 07927
- Gastroenterology Research Associates
-
-
New York
-
New York, New York, Estados Unidos, 10128
- Asher Kornbluth, MD
-
Rochester, New York, Estados Unidos, 14607
- Rochester Institute for Digestive Diseases and Sciences, Inc.
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28801
- Asheville Gastroenterology Associates, PA
-
Charlotte, North Carolina, Estados Unidos, 28211
- Carolina Digestive Health Associates
-
Pinehurst, North Carolina, Estados Unidos, 28374
- Pinehurst Medical Clinic
-
Raleigh, North Carolina, Estados Unidos, 27612
- Wake Research Associates, LLC.
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- Piedmont Medical Research Associates
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- University of Pittsburgh
-
-
South Carolina
-
Columbia, South Carolina, Estados Unidos, 29203
- Columbia Gastroenterology Associates, P.A.
-
-
Tennessee
-
German Town, Tennessee, Estados Unidos, 38138
- Gastroenterology Center Of The Midsouth
-
Nashville, Tennessee, Estados Unidos, 37205
- Nashville Medical Research Institute
-
-
Texas
-
Austin, Texas, Estados Unidos, 78745
- Austin Gastroenterology
-
-
Virginia
-
Christiansburg, Virginia, Estados Unidos, 24073
- New River Valley Research Institute
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Wisconsin Center for Advanced Research
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Is male or female aged 18 through 75 years.
- Has Crohn's disease diagnosed definitively prior to Screening (based upon clinical, endoscopic, radiologic imaging, or histological assessments).
- Has a Crohn's Disease Activity Index (CDAI) score of 220 to 450, inclusive at Baseline.
Exclusion Criteria:
- Has any clinically significant disease (eg, renal, hepatic, neurological, cardiovascular, pulmonary, endocrinologic, psychiatric, hematologic, urologic, or other acute or chronic illness) that, in the opinion of the investigator, would make the patient an unsuitable candidate for this study.
- Is a woman who has a positive pregnancy test, who is breast-feeding, or who is sexually active without using birth control during the course of the study and Follow-Up period.
- Is a woman of childbearing potential or a man who does not agree to use 2 forms of contraception during the course of the study and Follow-Up period.
- Has clinically significant hematologic, hepatic or renal laboratory abnormalities.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
Proportion of patients achieving clinical remission and clinical response at Day 29
|
Medidas de resultado secundarias
Medida de resultado |
---|
Proportion of patients achieving: a clinical remission at Days 29 and 43
|
a clinical response from Baseline to Day 29 and from Baseline to Day 43
|
a reduction in endoscopic scores from Baseline to Day 29
|
an increase in the Inflammatory Bowel Disease Questionnaire (IBDQ) score from Baseline to Days 29 and 43
|
a clinical remission or clinical response at Days 29 and 43 in the subset of patients with elevated C-reactive protein
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Bruce Sands, MD, Massachusetts General Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 5326-07
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Mesilato STA-5326
-
Synta Pharmaceuticals Corp.Terminado
-
National Institute of Allergy and Infectious Diseases...TerminadoEnfermedad de CrohnEstados Unidos
-
National Institute of Allergy and Infectious Diseases...TerminadoInmunodeficiencia Común VariableEstados Unidos
-
Synta Pharmaceuticals Corp.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...TerminadoEnfermedad de CrohnEstados Unidos
-
Emory UniversitySynta Pharmaceuticals Corp.TerminadoCarcinoma de células escamosas de la cavidad oral en estadio IVA | Carcinoma de células escamosas de laringe en estadio IVA | Carcinoma de células escamosas orofaríngeas en estadio IVA | Carcinoma de células escamosas de hipofaringe en estadio I | Carcinoma de células escamosas de laringe... y otras condicionesEstados Unidos
-
Genzyme, a Sanofi CompanyTerminado
-
Synta Pharmaceuticals Corp.TerminadoLinfoma | Leucemia | Neoplasias malignas hematológicas | Metastatic or Unresectable Solid TumorsEstados Unidos
-
Genzyme, a Sanofi CompanyTerminadoEnfermedad de CrohnIsrael, Estados Unidos, Rumania, Ucrania, Sudáfrica, Canadá, Australia, Bulgaria, Federación Rusa, Nueva Zelanda, Brasil
-
Genzyme, a Sanofi CompanyTerminadoEnfermedad de Crohn
-
David M. Jackman, MDMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals...TerminadoCáncer de pulmón de células pequeñasEstados Unidos